Chika Honjo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chika Honjo has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Akio Ikeda
Department of Epilepsy, Movement Disorders and Physiology, Kyoto University Graduate School of Medicine, Kyoto, Japan
1 shared publication - Akira Kuzuya
Department of Neurology, Kyoto University Graduate School of Medicine, Japan
1 shared publication - Atsushi Yonezawa
Kyoto University Hospital
1 shared publication - Ayae Kinoshita
School of Human Health Sciences, Faculty of Medicine Kyoto University Kyoto Japan
1 shared publication - Kazuya Goto
Department of Dermatology Kyoto University Graduate School of Medicine Kyoto Japan
1 shared publication - Kohei Okawa
Department of Neurology, Graduate School of Medicine Kyoto University Kyoto Japan
1 shared publication
Latest Publications
- Open Access
- 18 October 2023
- Published by Wiley in The FASEB Journal
- Vol. 37 (11) , e23252
Acute inhibition of AMPA receptors by perampanel reduces amyloid β‐protein levels by suppressing β‐cleavage of APP in Alzheimer's disease models
Hippocampal hyperexcitability is a promising therapeutic target to prevent Aβ deposition in AD since enhanced neuronal activity promotes presynaptic Aβ production and release. This article highlights the potential application of perampanel (PER), an AMPA receptor (AMPAR) antagonist approved for partial seizures, as a therapeutic agent for AD. Using transgenic AD mice combined with in vivo brain microdialysis and primary neurons under oligomeric Aβ‐evoked neuronal hyperexcitability, the acute effects of PER on Aβ metabolism were investigated. A single oral administration of PER rapidly decreased ISF Aβ 40 and Aβ 42 levels in the hippocampus of J20, APP transgenic mice, without affecting the Aβ 40 /Aβ 42 ratio; 5 mg/kg PER resulted in declines of 20% and 31%, respectively. Moreover, PER‐treated J20 manifested a marked decrease in hippocampal APP βCTF levels with increased FL‐APP levels. Consistently, acute treatment of PER reduced sAPPβ levels, a direct byproduct of β‐cleavage of APP, released to the medium in primary neuronal cultures under oligomeric Aβ‐induced neuronal hyperexcitability. To further evaluate the effect of PER on ISF Aβ clearance, a γ‐secretase inhibitor was administered to J20 1 h after PER treatment. PER did not influence the elimination of ISF Aβ, indicating that the acute effect of PER is predominantly on Aβ production. In conclusion, acute treatment of PER reduces Aβ production by suppressing β‐cleavage of amyloid‐β precursor protein effectively, indicating a potential effect of PER against Aβ pathology in AD.
- 18 October 2023
- Published by Wiley in The FASEB Journal
- Vol. 37 (11) , e23252
Open AccessAcute inhibition of AMPA receptors by perampanel reduces amyloid β‐protein levels by suppressing β‐cleavage of APP in Alzheimer's disease models
Hippocampal hyperexcitability is a promising therapeutic target to prevent Aβ deposition in AD since enhanced neuronal activity promotes presynaptic Aβ production and release. This article highlights the potential application of perampanel (PER), an AMPA receptor (AMPAR) antagonist approved for partial seizures, as a therapeutic agent for AD. Using transgenic AD mice combined with in vivo brain microdialysis and primary neurons under oligomeric Aβ‐evoked neuronal hyperexcitability, the acute effects of PER on Aβ metabolism were investigated. A single oral administration of PER rapidly decreased ISF Aβ 40 and Aβ 42 levels in the hippocampus of J20, APP transgenic mice, without affecting the Aβ 40 /Aβ 42 ratio; 5 mg/kg PER resulted in declines of 20% and 31%, respectively. Moreover, PER‐treated J20 manifested a marked decrease in hippocampal APP βCTF levels with increased FL‐APP levels. Consistently, acute treatment of PER reduced sAPPβ levels, a direct byproduct of β‐cleavage of APP, released to the medium in primary neuronal cultures under oligomeric Aβ‐induced neuronal hyperexcitability. To further evaluate the effect of PER on ISF Aβ clearance, a γ‐secretase inhibitor was administered to J20 1 h after PER treatment. PER did not influence the elimination of ISF Aβ, indicating that the acute effect of PER is predominantly on Aβ production. In conclusion, acute treatment of PER reduces Aβ production by suppressing β‐cleavage of amyloid‐β precursor protein effectively, indicating a potential effect of PER against Aβ pathology in AD.